

Supplemental data

Supplemental Tables

Table S1

Changes in marker gene expression domains after injection of hormone-inducible constructs with or without dexamethasone (DEX) treatments

Marker gene	DEX-treated controls	<i>GR-Six1</i> no DEX	<i>GR-Six1</i> DEX at cleavage	<i>GR-Eya1</i> no DEX	<i>GR-Eya1</i> DEX at cleavage
	% (n)	% (n)	% (n)	% (n)	% (n)
<i>Sox2</i> (placode)	4 ↓ (23); 0 e (23)	3 ↓ (76); 5 e (76)	85 ↓ (27); 36 e (22)	5 ↓ (21); 0 e (21)	50 ↓ (28); 36 e (28)
<i>NeuroD</i> (placode)	3 ↓ (29); 0 e (29)	12 ↓ (25)	58 ↓ (24); 0 e (24)	13 ↓ (29)	50 ↓ (12); 50 e (12)
<i>p27^{Xicl}</i> (placode)	NC (47); 0 e (47)	12 ↓ (16); 6 e (16)	67 ↓ (18); 39 e (18)	NC (20)	77 ↑ (13)

n: number of embryos analyzed at stages 16-22. NC: no change in expression compared to control side of same embryo. ↓: fainter expression or reduced expression domain; ↑: broader expression domain; e: ectopic expression domain.

Supplemental Figures

Fig. S1 Sequences and specificity of *Sox2* and *Sox3* morpholinos. The *Sox3* MO differed in 12 out of 25 positions from the *Sox2* sequence, 17 out of 25 positions from the *Sox1* sequence, and 15 out of 25 from the *SoxD* sequence. The *Sox2* MO differed from *Sox3* mRNA at 11 out of 25 positions, 17 out of 25 position from the *Sox1* sequence, and at 13 out of 25 positions from *SoxD*.